Literature DB >> 12727116

Multigene expression from a replicating adenovirus using native viral promoters.

Maxine Bauzon1, Daniel Castro, Michael Karr, Lynda K Hawkins, Terry W Hermiston.   

Abstract

We have developed a novel therapeutic gene delivery system for oncolytic adenoviruses that takes advantage of the endogenous gene expression machinery (promoters, splicing, polyadenylation signals) of the E3 transcription unit for gene delivery. In this work, we use two sites in the E3 region (6.7 K/gp19K and ADP sites) to demonstrate that (1) multiple therapeutic genes (MCP-3, TNFalpha) can be expressed from a single replicating Ad, (2) timing of expression of these therapeutic genes mimics that of the E3 region genes they replaced, (3) expression of the remaining genes in the complex E3 transcription unit is maintained, and (4) the multigene-expressing virus retains replication competence and ability to induce classical adenovirus cytopathic effects that parallel those of the parental adenovirus (ONYX-320). This system conserves the DNA packaging capacity of the size-constrained viral genome for therapeutic genes and can potentially be used to link therapeutic transgene expression to tumor-restricted viral replication. Potential clinical implications are discussed.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12727116     DOI: 10.1016/s1525-0016(03)00023-6

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  10 in total

1.  Transarterial injection of H101 in combination with chemoembolization overcomes recurrent hepatocellular carcinoma.

Authors:  Qing He; Yang Liu; Qing Zou; Yong-Song Guan
Journal:  World J Gastroenterol       Date:  2011-05-14       Impact factor: 5.742

2.  Linked tumor-selective virus replication and transgene expression from E3-containing oncolytic adenoviruses.

Authors:  Mingzhu Zhu; J Andrew Bristol; Yuefeng Xie; Mervat Mina; Hong Ji; Suzanne Forry-Schaudies; David L Ennist
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

3.  Intra-tumor injection of H101, a recombinant adenovirus, in combination with chemotherapy in patients with advanced cancers: a pilot phase II clinical trial.

Authors:  Wei Lu; Shu Zheng; Xu-Feng Li; Jian-Jin Huang; Xiao Zheng; Zhen Li
Journal:  World J Gastroenterol       Date:  2004-12-15       Impact factor: 5.742

Review 4.  Armed replicating adenoviruses for cancer virotherapy.

Authors:  J J Cody; J T Douglas
Journal:  Cancer Gene Ther       Date:  2009-02-06       Impact factor: 5.987

5.  INGN 007, an oncolytic adenovirus vector, replicates in Syrian hamsters but not mice: comparison of biodistribution studies.

Authors:  B Ying; K Toth; J F Spencer; J Meyer; A E Tollefson; D Patra; D Dhar; E V Shashkova; M Kuppuswamy; K Doronin; M A Thomas; L A Zumstein; W S M Wold; D L Lichtenstein
Journal:  Cancer Gene Ther       Date:  2009-02-06       Impact factor: 5.987

6.  Oncolytic viruses: the power of directed evolution.

Authors:  Maxine Bauzon; Terry W Hermiston
Journal:  Adv Virol       Date:  2011-07-24

Review 7.  Armed therapeutic viruses - a disruptive therapy on the horizon of cancer immunotherapy.

Authors:  Maxine Bauzon; Terry Hermiston
Journal:  Front Immunol       Date:  2014-02-24       Impact factor: 7.561

Review 8.  Effect of Transgene Location, Transcriptional Control Elements and Transgene Features in Armed Oncolytic Adenoviruses.

Authors:  Martí Farrera-Sal; Cristina Fillat; Ramon Alemany
Journal:  Cancers (Basel)       Date:  2020-04-23       Impact factor: 6.639

9.  An empty E1, E3, E4 adenovirus vector protects photoreceptors from light-induced degeneration.

Authors:  Hiroyasu Takita; Shin Yoneya; Peter L Gehlbach; Lisa L Wei; Keisuke Mori
Journal:  J Ocul Biol Dis Infor       Date:  2008-05-22

10.  Recombinant bovine adenovirus-3 co-expressing bovine respiratory syncytial virus glycoprotein G and truncated glycoprotein gD of bovine herpesvirus-1 induce immune responses in cotton rats.

Authors:  Robert Brownlie; Pankaj Kumar; Lorne A Babiuk; Suresh Kumar Tikoo
Journal:  Mol Biotechnol       Date:  2015-01       Impact factor: 2.860

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.